Patrick Lu

Sirnaomics, Inc. develops novel targeted therapeutics for critical human diseases. It discovers and develops RNAi therapeutics. The firm pursues its proprietary technologies using pluripotent siRNA cocktail design and nanoparticle-enhanced therapeutic delivery to treat critical human diseases. The company was founded by Patrick Y. Lu, George Ji and David M. Evans in 2007 and is headquartered in Gaithersburg, MD.

Part of Sirnaomics, Inc., Guangzhou Natai Biomedical Technology Co., Ltd. is a company that manufactures biomedical products. The company is based in Guangzhou, China. Guangzhou Natai Biomedical Technology Co. was acquired by Sirnaomics Biopharmaceuticals (Suzhou) Co., Ltd. The Chinese company was founded in 2012 by Yang Lu, Jian Jun Ji, Sheng Gao Tang. Sheng Gao Tang has been the CEO since 2012.

Part of Sirnaomics, Inc., Sirnaomics Biopharmaceuticals (Suzhou) Co., Ltd. is a Chinese company that develops nucleic acid drugs. The company is based in Suzhou, China. The company was founded in 2008 by Yang Lu, David Mark Evans. Yang Lu has been the CEO since 2008.

Intradigm Corp. develops drugs and therapies. Its RNAi therapeutic platform comprised of proprietary delivery technologies, potent siRNA sequences and innovative siRNA structural features. The company was founded by Puthupparampil Scaria, Martin C. Woodle, Wei-Wu He and Patrick Y. Lu in 2000 and is headquartered in Palo Alto, CA.